Market Intelligence, Clinical Progress, and High-Purity Reagents for NTRK Fusion Oncology, Neurodegeneration, and Neurotrophic Signaling Research.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for TrkB/NTRK2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | NTRK2 ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1EU/µg. Sequence Verified. HEK293 Expressed (Native Glycosylation). Ideal for BDNF-competitive binding assays and ADC conjugation. |
View NTRK2 Products |
| Gene Delivery | NTRK2 Promise-ORF / Lentivirus Full-length human NTRK2 (FL-TrkB) and dominant-negative TrkB.T1 isoform. For stable cell line construction, signaling assays, and BBB co-culture models. |
View NTRK2 Products |
| Benchmark Ab | Anti-NTRK2 (TrkB) Recombinant Antibody (Reference Clone) Sequence-verified positive control for detection, FACS, binding, and neutralization assays. |
View NTRK2 Products |
| Validator | NTRK2 siRNA Set For knockdown verification and specificity controls in cell-based assays. |
View NTRK2 Products |
| Related Target A | NTRK1 (TrkA) Essential for pan-Trk inhibitor selectivity counter-screening; major off-target liability. |
View NTRK1 Products |
| Related Target B | NTRK3 (TrkC) Required for subfamily selectivity profiling to differentiate TrkB-specific versus pan-Trk modalities. |
View NTRK3 Products |
| Ligand Control | BDNF (Brain-Derived Neurotrophic Factor) Native high-affinity ligand for competition binding and activation assays (Kd ~10⁻¹¹ M). |
View BDNF Products |
| Co-receptor | NGFR (p75NTR) Modulates TrkB signaling and determines survival vs apoptosis outcomes; essential for neurological indication modeling. |
View NGFR Products |
Critical Assay Challenges & The TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Pan-Trk Selectivity Profiling (TrkA/TrkC Off-Target) | Human NTRK1/NTRK2/NTRK3 Ortholog Panel available with >95% purity; Sequence-verified ECD-Fc for parallel SPR/binding studies. |
| Resistance Mutation Coverage (Solvent Front/Activation Loop) | Clinical mutant panel including UniProt-curated mutations (lung adenocarcinoma somatic mutation, rs1047856, DEE58) and solvent front/gatekeeper analogs; Recombinant kinase domains with theoretical MW confirmed by Mass Spec. |
| CNS Penetration & BBB Modeling | Full-length Lentivirus Particles (FL-TrkB & TrkB.T1) for stable BBB endothelial co-culture models; Human/Mouse/Cynomolgus ECD proteins for cross-species bridging. |
| Cross-Species Toxicology (Cyno/Mouse) | Human/Mouse/Cynomolgus NTRK2 ECD proteins with aligned epitope regions for pre-species bridging studies; >95% purity. |
| False Positives & Isoform Interference | Validated siRNA included for target-specificity verification; Endotoxin-controlled (<1 EU/µg) to eliminate TLR4 artifacts; Dominant-negative TrkB.T1 and full-length controls for isoform discrimination. |
Live TrkB/NTRK2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TrkB/NTRK2-targeted therapeutics is bifurcating into oncology and neurology fronts. In oncology, first-generation pan-Trk inhibitors (larotrectinib, entrectinib) have established standard of care for NTRK fusion-positive solid tumors, but acquired resistance mutations (solvent front, gatekeeper) drive development of next-generation selective and CNS-penetrant inhibitors. Neurologically, the TrkB/BDNF axis is gaining attention for neurodegenerative disorders (Alzheimer's, MDD, ALS) and obesity, requiring agonist mechanisms with strict selectivity vs TrkA/TrkC and avoidance of p75NTR-mediated apoptosis. Emerging modalities include ADC for TrkB-high tumors and biologic agonists. The market is expected to shift toward mutant-selective inhibitors by 2026–2027, with CNS-penetrant formulations dominating brain metastasis treatment.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Pan-Trk / Type I/II Kinase Inhibitors | Bayer (Larotrectinib), Roche (Entrectinib), BMS (Repotrectinib) | NTRK Fusion+ Solid Tumors | Resistance Mutant Panel (solvent front, gatekeeper); Selectivity vs NTRK1/3 |
| CNS-Penetrant / Next-Gen TRK Inhibitors | Taiho Oncology, CStone Pharmaceuticals, Eli Lilly/Loxo | Brain Metastases, Primary Brain Tumors | Cell-based BBB Models using NTRK2 Lentivirus Stable Lines; Cross-species ECD proteins |
| ADC (Emerging) | Various Preclinical | TrkB-High Expressing Tumors | High-Affinity ECD-Fc for Conjugation; Internalization Assays |
| Biologic Agonists / BDNF Mimetics | Neurotrophic Biologics (Preclinical) | Depression, Alzheimer's, ALS, Obesity | p75NTR Co-receptor Assays; BDNF Competition Binding; Receptor Activation Assays |